The finasteride prostate cancer prevention trial (PCPT) - What have we learned?

European Journal of Cancer

Volumn 41, Issue 13, 2005, Pages 2016-2022

  Mellon, J Kilian ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Chemoprevention; Finasteride; PCPT; Prostate cancer

Indexed keywords

FINASTERIDE;

CANCER INCIDENCE; CLINICAL FEATURE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MORTALITY; PATHOLOGY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; REVIEW;

EID: 27644507805     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.06.010     Document Type: Article

References (19)

1. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349, 215-224.
2. Feigl P, Blumenstein B, Thompson IM, et al. Design of the prostate cancer prevention trial. Control Clin Trials 1995, 16, 150-163.
3. Thompson IM, Klein EA, Lippman SM, et al. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003, 44, 650-655.
4. Klein EA. Chemoprevention of prostate cancer. Crit Rev Oncol Haematol 2005, 54, 1-10.
5. Pitts Jr WR. The clinical implications of the Prostate Cancer Prevention Trial (PCPT). BJU Int 2004, 93, 1120-1121.
6. Pitts Jr WR. Letter re: chemoprevention of urological cancer. J Urol 2000, 163, 1260-1261.
7. Silver RI, Wiley EL, Davis DL, et al. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Ural 1994,152, 433-437.
8. Luo J, Dunn TA, Ewing CM, et al. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate cancer. Prostate 2003, 57, 134-139.
9. Imanov O, Lopatkin NA, Gustafsson J-A. Estrogen receptor β in prostate cancer. N Engl J Med 2004, 351, 2773-2774.
10. Reuter VE. Pathologic changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 1997, 49, 16-22.
11. Bostwick DG, Ramnani D, Cheng L. Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation and radiotherapy. Urol Clin North Am 1999, 26, 465-479.
12. Civantos F, Watson RB, Pinto JE. Finasteride effect on prostatic hyperplasia and prostate cancer. J Urol Pathol 1997, 6, 1-13.
13. Yang XJ, Lecksell K, Short K, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy. Urology 1998, 53, 696-700.
14. Carver BS, Kattan MW, Scardino PT, et al. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 2005, 95, 509-512.
15. Tempany CM, Partin AW, Zerhouni EA, et al. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate 1993, 22, 39-42.
16. Marks LS, Partin AW, Dorey FJ, et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999, 53, 574-580.
17. Lucia MS, Darke A, Goodman P, et al. Pathological assessment of high grade tumours in the Prostate Cancer Prevention Trial (PCPT). J Urol 2005, 173(4). abstract #1664.
18. Unger JM, Thompson IM, LeBlanc ML, et al. Estimated impact of the prostate cancer prevention trial on population mortality. Cancer 2005, 103, 1375-1380.
19. Lotan Y, Cadeddu JA, Lee JJ, et al. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol 2005, 23, 1911-1920.